TP53 mutation at codon 179 metabolically reprograms cancer cells to promote invasion.
Saved in:
| Title: | TP53 mutation at codon 179 metabolically reprograms cancer cells to promote invasion. |
|---|---|
| Authors: | Sarkar D; Department of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand.; Maurice Wilkins Centre for Biodiscovery, Auckland, New Zealand., Gyanwali GC; Department of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand.; Maurice Wilkins Centre for Biodiscovery, Auckland, New Zealand., Patel J; Department of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand., Shevchuk P; Department of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand.; Maurice Wilkins Centre for Biodiscovery, Auckland, New Zealand., Jeffs A; Department of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand., Woolley AG; Department of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand.; Maurice Wilkins Centre for Biodiscovery, Auckland, New Zealand., Wang S; Department of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand.; Maurice Wilkins Centre for Biodiscovery, Auckland, New Zealand., Sardari M; Department of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand.; Maurice Wilkins Centre for Biodiscovery, Auckland, New Zealand., Bhandarkar A; Department of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand.; Maurice Wilkins Centre for Biodiscovery, Auckland, New Zealand., Siddiqui H; Maurice Wilkins Centre for Biodiscovery, Auckland, New Zealand.; Department of Biochemistry, University of Otago, Dunedin, New Zealand., Ratajska M; Department of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand.; Maurice Wilkins Centre for Biodiscovery, Auckland, New Zealand.; Division of Pathology and Neuropathology, Medical University of Gdansk, Gdansk, Poland., Sarwar M; Maurice Wilkins Centre for Biodiscovery, Auckland, New Zealand.; Department of Obstetrics and Gynaecology, University of Otago, Christchurch, New Zealand., Kannan S; Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore., Verma CS; Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.; Department of Biological Sciences, National University of Singapore, Singapore, Singapore.; School of Biological Sciences, Nanyang Technological University, Singapore, Singapore., Drummond CJ; Department of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand.; Maurice Wilkins Centre for Biodiscovery, Auckland, New Zealand., McKinney C; Department of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand., Antony J; Department of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand., McCormick SP; Maurice Wilkins Centre for Biodiscovery, Auckland, New Zealand.; Department of Biochemistry, University of Otago, Dunedin, New Zealand., Braithwaite A; Department of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand.; Maurice Wilkins Centre for Biodiscovery, Auckland, New Zealand., Mehta S; Department of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand. sunali.mehta@otago.ac.nz.; Maurice Wilkins Centre for Biodiscovery, Auckland, New Zealand. sunali.mehta@otago.ac.nz. |
| Source: | Cancer gene therapy [Cancer Gene Ther] 2026 Jun 05. Date of Electronic Publication: 2026 Jun 05. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9432230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5500 (Electronic) Linking ISSN: 09291903 NLM ISO Abbreviation: Cancer Gene Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
